PL2162456T3 - Stabilny, krystaliczny kwas (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowy, sposób jego wytwarzania i zastosowanie - Google Patents

Stabilny, krystaliczny kwas (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowy, sposób jego wytwarzania i zastosowanie

Info

Publication number: PL2162456T3
Authority: PL; Poland
Prior art keywords: methyl; tetrahydrofolic acid; calcium salt; aqueous solution; acid
Prior art date: 2007-05-30

Application number

PL08748372T

Other languages

English (en)

Inventor

Raffella Manzotti

Moreno Morosoli

Original Assignee

Cerbios Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-30

Filing date

2008-05-29

Publication date

2011-12-30

2008-05-29 Application filed by Cerbios Pharma Sa filed Critical Cerbios Pharma Sa

2011-12-30 Publication of PL2162456T3 publication Critical patent/PL2162456T3/pl

Links

ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title abstract 6
239000007864 aqueous solution Substances 0.000 abstract 4
159000000007 calcium salts Chemical class 0.000 abstract 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
239000001110 calcium chloride Substances 0.000 abstract 2
229910001628 calcium chloride Inorganic materials 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000000243 solution Substances 0.000 abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 abstract 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
210000004102 animal cell Anatomy 0.000 abstract 1
JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
210000005260 human cell Anatomy 0.000 abstract 1
ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 abstract 1
230000001035 methylating effect Effects 0.000 abstract 1
239000011541 reaction mixture Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL08748372T 2007-05-30 2008-05-29 Stabilny, krystaliczny kwas (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowy, sposób jego wytwarzania i zastosowanie PL2162456T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH00856/07A CH698729B1 (de)	2007-05-30	2007-05-30	Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP08748372A EP2162456B1 (de)	2007-05-30	2008-05-29	Stabile kristalline (6S) -N (5) -Methyl-5,6,7,8-tetrahydrofolsäure, deren Herstellung und Verwendung
PCT/CH2008/000242 WO2008144953A1 (de)	2007-05-30	2008-05-29	Verfahren zur herstellung des stabilen, amorphen calciumsalzes von (6s) -n (5) -methyl-5, 6, 7, 8-tetrahydrofolsäure

Publications (1)

Publication Number	Publication Date
PL2162456T3 true PL2162456T3 (pl)	2011-12-30

Family

ID=38617354

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL08748372T PL2162456T3 (pl)	2007-05-30	2008-05-29	Stabilny, krystaliczny kwas (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowy, sposób jego wytwarzania i zastosowanie
PL11003589T PL2354142T3 (pl)	2007-05-30	2008-05-29	Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowego

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL11003589T PL2354142T3 (pl)	2007-05-30	2008-05-29	Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowego

Country Status (10)

Country	Link
US (2)	US8314102B2 (pl)
EP (2)	EP2162456B1 (pl)
JP (1)	JP5552422B2 (pl)
AT (1)	ATE515507T1 (pl)
AU (1)	AU2008255518C1 (pl)
CA (1)	CA2686519C (pl)
CH (1)	CH698729B1 (pl)
ES (2)	ES2366500T3 (pl)
PL (2)	PL2162456T3 (pl)
WO (1)	WO2008144953A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102516247A (zh) *	2010-12-15	2012-06-27	连云港金康医药科技有限公司	A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2502625A1 (en) *	2011-03-21	2012-09-26	GMT Fine Chemicals SA	Process for the preparation of crystalline levofolinic acid
IN2014DN06942A (pl)	2012-01-20	2015-04-10	Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
CN104557937B (zh) *	2012-01-20	2017-03-08	连云港金康和信药业有限公司	(6s)‑5‑甲基四氢叶酸盐晶型及其制备方法
CN102584826B (zh) *	2012-01-20	2015-04-29	连云港金康医药科技有限公司	(6s)-5-甲基四氢叶酸盐晶型及其制备方法
CN103694239B (zh) *	2012-09-27	2016-12-21	上海科胜药物研发有限公司	一种5‑甲基‑（6s）‑四氢叶酸晶型a及其制备方法
EP2781214A1 (en)	2013-03-22	2014-09-24	Chemo Research, S.L.	Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN103214487A (zh) *	2013-04-12	2013-07-24	张家港威胜生物医药有限公司	一种重要医药化工原料(6s)-5-甲基四氢叶酸盐的合成
CA2974953A1 (en)	2015-01-27	2016-08-04	La Vita Compounding Pharmacy	Stable 5-methyltetrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1572137A (en) *	1977-02-22	1980-07-23	Bioresearch Sas Del Dr Livio C	Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
DE3821875C1 (pl) *	1988-06-29	1990-02-15	Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
CH680731A5 (pl) *	1990-04-12	1992-10-30	Sapec Fine Chemicals
CH681303A5 (pl) *	1991-01-16	1993-02-26	Eprova Ag
DE4136921A1 (de)	1991-11-11	1993-05-13	Knoll Ag	Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
CH686672A5 (de) *	1992-12-01	1996-05-31	Cerbios Pharma Sa	Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure.
JPH06271480A (ja) *	1993-03-17	1994-09-27	Sekisui Chem Co Ltd	有機非線形光学材料の製造方法
CH693905A5 (de) *	1999-04-15	2004-04-15	Eprova Ag	Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
JP2001072675A (ja) *	1999-06-30	2001-03-21	Takeda Chem Ind Ltd	ベンズイミダゾール化合物の結晶
TWI377206B (en) *	2005-04-06	2012-11-21	Theravance Inc	Crystalline form of a quinolinone-carboxamide compound
JPWO2006121151A1 (ja) *	2005-05-13	2008-12-18	第一三共株式会社	１−メチルカルバペネム化合物の結晶

2007
- 2007-05-30 CH CH00856/07A patent/CH698729B1/de unknown
2008
- 2008-05-29 US US12/601,207 patent/US8314102B2/en active Active
- 2008-05-29 WO PCT/CH2008/000242 patent/WO2008144953A1/de not_active Ceased
- 2008-05-29 AU AU2008255518A patent/AU2008255518C1/en active Active
- 2008-05-29 ES ES08748372T patent/ES2366500T3/es active Active
- 2008-05-29 JP JP2010509650A patent/JP5552422B2/ja active Active
- 2008-05-29 EP EP08748372A patent/EP2162456B1/de active Active
- 2008-05-29 PL PL08748372T patent/PL2162456T3/pl unknown
- 2008-05-29 AT AT08748372T patent/ATE515507T1/de active
- 2008-05-29 EP EP11003589.6A patent/EP2354142B1/de active Active
- 2008-05-29 PL PL11003589T patent/PL2354142T3/pl unknown
- 2008-05-29 ES ES11003589T patent/ES2430113T3/es active Active
- 2008-05-29 CA CA2686519A patent/CA2686519C/en active Active
2012
- 2012-08-14 US US13/585,627 patent/US8754212B2/en active Active

Also Published As

Publication number	Publication date
US8754212B2 (en)	2014-06-17
ES2366500T3 (es)	2011-10-20
CA2686519A1 (en)	2008-12-04
JP2010528059A (ja)	2010-08-19
AU2008255518C1 (en)	2012-01-12
US20100168117A1 (en)	2010-07-01
AU2008255518B2 (en)	2011-08-25
JP5552422B2 (ja)	2014-07-16
US8314102B2 (en)	2012-11-20
US20130040956A1 (en)	2013-02-14
WO2008144953A1 (de)	2008-12-04
CA2686519C (en)	2012-12-18
EP2354142B1 (de)	2013-07-31
EP2354142A1 (de)	2011-08-10
PL2354142T3 (pl)	2014-01-31
ES2430113T3 (es)	2013-11-19
CH698729B1 (de)	2009-10-15
EP2162456B1 (de)	2011-07-06
EP2162456A1 (de)	2010-03-17
ATE515507T1 (de)	2011-07-15
AU2008255518A1 (en)	2008-12-04

Publication	Publication Date	Title
PL2354142T3 (pl)	2014-01-31	Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowego
PH12019500930A1 (en)	2019-08-19	PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
EP4282482A3 (en)	2024-01-17	Nucleoside phosphoramidate prodrugs
NZ601689A (en)	2014-11-28	Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
NZ702041A (en)	2016-03-31	Heterocyclic containing entities, compositions and methods
UA89123C2 (ru)	2009-12-25	Производные пиримидина для лечения абнормального роста клеток
PL159180B1 (pl)	1992-11-30	[/Z/-2-/2-aminotiazolilo-4/ -4-karboksybuten-2-oiloamino]-3- cefemokarboksylowego-4 PL PL PL
MX2009009843A (es)	2009-09-24	Compuestos espiro sustituidos como inhibidores de la angiogenesis.
WO2009150137A3 (en)	2010-02-18	Pyrazine derivatives as epithelial sodium channel blockers
MD20140103A2 (ro)	2015-01-31	Inhibitori ai diacilglicerol aciltransferazei 2
TW200517393A (en)	2005-06-01	Processes for the preparation of benzoimidazole derivatives
MX2009005413A (es)	2009-06-01	Formas cristalinas del acido zoledronico.
BR112014012942A2 (pt)	2017-06-13	uso de derivados de aril para controle de ectoparasitas
CN103261197A (zh)	2013-08-21	溶解性高的吡咯并喹啉醌盐及其制造方法
UA100524C2 (ru)	2013-01-10	СПОСОБ ПОВЫШЕНИЯ ЗНАЧЕНИЯ рН КИСЛЫХ ВОДОЕМОВ
PL1751093T3 (pl)	2011-04-29	Podstawione pochodne kwasu cykloheksylooctowego
MX2021000683A (es)	2021-05-31	Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.
JP5960460B2 (ja)	2016-08-02	結晶性レボホリン酸及びその調製方法
PL81921B1 (pl)	1975-10-31
CN114230454B (zh)	2023-12-12	没食子酸类天然活性成分的钙配合物及其合成方法和应用
NZ593344A (en)	2013-08-30	Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics
ES2267421T1 (es)	2007-03-16	Procedimiento para la preparacion de acido (6rs)-n(5)-formil-5,6,7,8-tetrahidrofolico cristalino.
TW201720788A (zh)	2017-06-16	3-羥基異戊酸之一價陽離子鹽之結晶及該結晶之製造方法
RU2290395C8 (ru)	2007-06-27	Способ получения сукцината кальция
US20040214884A1 (en)	2004-10-28	Method for supplementing magnesium in an animal